Treatment Resistant Depression - Pipeline Review, H2 2016

  • ID: 3946487
  • Drug Pipelines
  • 74 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc.
  • Axsome Therapeutics Inc
  • Eli Lilly and Company
  • Evotec AG
  • Johnson & Johnson
  • MORE
Treatment Resistant Depression - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Treatment Resistant Depression - Pipeline Review, H2 2016, provides an overview of the Treatment Resistant Depression (Central Nervous System) pipeline landscape.

Treatment resistant depression (TRD) is an episode of major depressive disorder that does not respond to an antidepressant medication. Symptoms include difficulty concentrating, fatigue, insomnia, overeating or appetite loss and persistent aches or pains, headaches, cramps, or digestive problems. Treatment includes antidepressant from a different drug class, antipsychotic medication, electroconvulsive therapy (ECT) and vagus nerve stimulation.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Treatment Resistant Depression - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Treatment Resistant Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Treatment Resistant Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Treatment Resistant Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 4 and 6 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Treatment Resistant Depression.

Treatment Resistant Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Treatment Resistant Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Treatment Resistant Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Treatment Resistant Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Treatment Resistant Depression (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Treatment Resistant Depression (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Treatment Resistant Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc.
  • Axsome Therapeutics Inc
  • Eli Lilly and Company
  • Evotec AG
  • Johnson & Johnson
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Treatment Resistant Depression Overview

Therapeutics Development

Pipeline Products for Treatment Resistant Depression - Overview

Pipeline Products for Treatment Resistant Depression - Comparative Analysis

Treatment Resistant Depression - Therapeutics under Development by Companies

Treatment Resistant Depression - Therapeutics under Investigation by Universities/Institutes

Treatment Resistant Depression - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Treatment Resistant Depression - Products under Development by Companies

Treatment Resistant Depression - Products under Investigation by Universities/Institutes

Treatment Resistant Depression - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Amorsa Therapeutics Inc.

Avanir Pharmaceuticals, Inc.

Axsome Therapeutics Inc

Biohaven Pharmaceutical Holding Company Limited

Eli Lilly and Company

Evotec AG

Johnson & Johnson

Otsuka Holdings Co., Ltd.

Relmada Therapeutics, Inc.

Reviva Pharmaceuticals Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Takeda Pharmaceutical Company Limited

Treatment Resistant Depression - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(bupropion hydrochloride + dextromethorphan hydrobromide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(dextromethorphan + quinidine sulfate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMS-410 FA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMS-520 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVP-786 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CX-157 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DSP-1200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

esketamine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EVT-100 Series - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-341495 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REL-1017 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

riluzole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Insomnia, Obesity and Treatment Resistant Depression - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-653 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0431316 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Treatment Resistant Depression - Dormant Projects

Treatment Resistant Depression - Discontinued Products

Treatment Resistant Depression - Product Development Milestones

Featured News & Press Releases

Mar 17, 2016: Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression

Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis

Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Treatment Resistant Depression, H2 2016

Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Treatment Resistant Depression - Pipeline by Addex Therapeutics Ltd, H2 2016

Treatment Resistant Depression - Pipeline by Amorsa Therapeutics Inc., H2 2016

Treatment Resistant Depression - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016

Treatment Resistant Depression - Pipeline by Axsome Therapeutics Inc, H2 2016

Treatment Resistant Depression - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016

Treatment Resistant Depression - Pipeline by Eli Lilly and Company, H2 2016

Treatment Resistant Depression - Pipeline by Evotec AG, H2 2016

Treatment Resistant Depression - Pipeline by Johnson & Johnson, H2 2016

Treatment Resistant Depression - Pipeline by Otsuka Holdings Co., Ltd., H2 2016

Treatment Resistant Depression - Pipeline by Relmada Therapeutics, Inc., H2 2016

Treatment Resistant Depression - Pipeline by Reviva Pharmaceuticals Inc., H2 2016

Treatment Resistant Depression - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016

Treatment Resistant Depression - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Treatment Resistant Depression - Dormant Projects, H2 2016

Treatment Resistant Depression - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Treatment Resistant Depression, H2 2016

Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Addex Therapeutics Ltd
Amorsa Therapeutics Inc.
Avanir Pharmaceuticals, Inc.
Axsome Therapeutics Inc
Biohaven Pharmaceutical Holding Company Limited
Eli Lilly and Company
Evotec AG
Johnson & Johnson
Otsuka Holdings Co., Ltd.
Relmada Therapeutics, Inc.
Reviva Pharmaceuticals Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll